Summary
In order to obtain rapid blood clearance of circulating antibodies (Ab) at a desired time, cross-linking reagents such as second Ab are often employed. Such reagents will generally bind to Ab located at the tumor site as well as free Ab, and we therefore investigated whether the cross-linking of Ab bound to the surface of tumor cells affects the processing of those Ab. Cross-linking was induced in various ways: a polyclonal second Ab [rabbit anti-(mouse IgG)], a monoclonal rat anti-(mouse IgG constant region) Ab, and streptavidin used in conjunction with a biotinylated first Ab. Processing was followed for 3 days, to allow nearly all of the bound Ab to reach its ultimate fate. Results depended strongly on the particular first Ab used. Two basic effects were observed. First, the second Ab efficiently prevented the early dissociation of intact Ab from the cell; once the second Ab bound, there was virtually no dissociation of the primary Ab bound to the cells. For most Ab, where only a small proportion of bound Ab dissociated intact, this effect was relatively small. However, for an unusual Ab, where the majority dissociated intact (L6) the effect of a second Ab in prolonging Ab retention by the cell was dramatic. Second, cross-linking sometimes resulted in markedly accelerated internalization and degradation of the bound Ab, coupled with the release of degradation products into the medium. This process resulted in much shorter retention of the radioisotope by the cell. If a “residualizing” radiolabel was used,125I-dilactitoltyramine, which is probably trapped within lysosomes after Ab catabolism, the effect of the second Ab in accelerating loss from the cell was largely prevented. We also tested anti-idiotype Ab as cross-linking reagents. In addition to testing anti-idiotype Ab known to react with the cell-bound primary Ab, we also tested antiidiotype Ab not expected to bind to cell-bound Ab, initially as a negative control. Unexpectedly, all anti-indiotype Ab tested induced rapid release of the primary Ab from the cell. This effect was similar to the effect of a large excess of unlabeled Ab, and we attribute it to the blocking of the free binding site of a “wobbling” Ab, which prevents its rebinding to a second antigen molecule. We conclude that the use of selected anti-idiotype Ab to clear circulating Ab, while not reacting with cell-bound Ab, must be done cautiously. These effects must be taken into consideration in developing procedures that utilize second Ab or other crosslinking agents.
Similar content being viewed by others
References
Bagshawe KD (1989) Towards generating cytotoxic agents at cancer sites. Br J Cancer 60: 275
Blumenthal RD, Sharkey RM, Snyder D, Goldenberg DM (1989) Reduction by anti-antibody administration of the radiotoxicity associated with131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy. J Natl Cancer Inst 81: 194
Bona CA, Kang C-Y, Kohler H, Monestier M (1986) Epibody: the image of the network created by a single antibody. Immunol Rev 90: 115
Duncan JR, Welch MJ (1993) Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 34: 1728
Hellstrom KE, Yelton DE, Fell HP, Beaton D, Gayle M, MacLean M, Kaha M, Hellstrom I (1990) Epitope mapping and use of antiidiotypic antibodies to the L6 monoclonal anticarcinoma antibody. Cancer Res 50: 2449
Huet C, Ash JF, Singer SJ (1980) The antibody induced clustering and endocytosis of HLA antigens on cultured human fibroblasts. Cell 21: 429
Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ (1992) The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 52: 835
Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB (1994) Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 73: 787
Matzku S, Tilgen W, Kalthoff H, Schmiegel WH, Brocker E-B (1988) Dynamics of antibody transport and internalization. Int J Cancer [Suppl] 2: 11
Matzku S, Moldenhaur G, Kalthoff H, Canevari S, Colnaghi M, Schuhmacher J, Bihl II (1990) Antibody transport and internalization into tumors. Br J Cancer 62 [suppl X]: 1
Merck Index, 9th edn (1976) Merck, Rahway, NJ, p 1244
Ong GL, Mattes MJ (1989) Penetration and binding of antibodies in experimental human solid tumors grown in mice. Cancer Res 49: 4264
Ong GL, Ettenson D, Sharkey RM, Marks A, Baumal R, Goldenberg DM, Mattes MJ (1991) Galactose-conjugated antibodies in cancer therapy: properties and principles of action. Cancer Res 51: 1619
Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, Rossetti C, Malcovati M, Chiolerio F, Seccamani E, Siccardi AG, Fazio F (1991) Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 51: 5960
Pedley RB, Dale R, Boden JA, Begent RHJ, Keep PA, Green AJ (1989) The effect of second antibody clearance on the distribution and dosimetry of radiolabelled anti-CEA antibody in a human colonic tumour xenograft model. Int J Cancer 43: 713
Pimm MV, Gribben SJ (1992) Evaluation of monoclonal idiotypicspecific antibodies as clearing antibodies for enhancement of target localisation by tumor-specific monoclonal antibodies: diversity of effects in nude mice with human tumor xenografts. Eur J Nucl Med 19: 436
Schreiner GF, Unanue ER (1976) Membrane and cytoplasmic changes induced by ligand-surface immunoglobulin interaction. Adv Immunol 24: 37
Sgouros G (1992) Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis. J Nucl Med 33: 2167
Sharkey RM, Mabus J, Goldenberg DM (1988) Factors influencing anti-antibody enhancement of tumor targeting with antibodies in hamsters with human colonic tumor xenografts. Cancer Res 48: 2005
Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegal JA, Goldenberg DM (1990) Biodistribution and radiation dose estimates for yttrium-and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 50: 2330
Sharkey RM, Boerman OC, Natale A, Pawlyk D, Monestier M, Losman MJ, Goldenberg DM (1992) Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic antiidiotype antibody in tumor-bearing nude mice. Int J Cancer 51: 266
Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, Goldenberg DM, Matters MJ (1994) The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 35: 899
Strobel JL, Baynes JW, Thorpe SR (1985)125I-glycoconjugate labels for identifying sites of protein catabolism in vivo: effect of structure and chemistry of coupling to protein on label entrapment in cells after protein degradation. Arch Biochem Biophys 240: 635
Waldmann TA, Strober W (1969) Metabolism of immunoglobulins. Prog Allergy 13: 1
Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD, Cosand WL (1994) Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 54: 2719
Weadock KS, Sharkey RM, Varga DC, Goldenberg DM (1990) Evaluation of a remote radioiodination system for radio-immunotherapy. J Nucl Med 31; 508
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ong, G.L., Marria, V. & Mattes, M.J. The fate of antibodies and their radiolabels bound to tumor cells in vitro: The effect of cross-linking at the cell surface and of anti-idiotype antibodies. Cancer Immunol Immunother 39, 325–331 (1994). https://doi.org/10.1007/BF01519986
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01519986